Emphasising safety and sustainability in circular design A stronger focus on safety, health and sustainability is needed in designing circular products. When basic resources are re-used in new products, health risks should be avoided.
Measures against polluting microplastics from garments When garments made from synthetic materials wear, due to use and washing, microplastic fibres are released. Wastewater treatment plants remove 50 to 90 per cent of these microplastic fibres.
Sustainability Day at RIVM: Microplastics Today, 10 October 2018, is national Sustainability Day in the Netherlands.
Research: HPV vaccine is safe RIVM research shows no causal link between the vaccine against cervical cancer (HPV) and long-term fatigue symptoms in girls.
Large increase in legionellosis in the Netherlands The Municipal Public Health Services (GGD) received 561 reports of legionellosis over the past year. Never before has RIVM registered as many reports of this disease as in the past year.
Meningococcal type W most notable infectious disease in 2017 The report ‘State of Infectious Diseases in the Netherlands in 2017’ published by RIVM today, provides an overview of the most important developments in infectious diseases in the Netherlands and a
Disease burden and cost-of-illness of food-related pathogens in the Netherlands Each year, RIVM presents an update on the number of illnesses caused by 14 enteric pathogens (such as Salmonella, Campylobacter or Listeria) that can be transmitted by food into the human body.
Measures to reduce microplastic emissions in the environment Microplastics are plastic particles that are smaller than 5 millimetres; through the use of plastic or rubber products these microplastics can end up in the environment (surface water, soil, and ai
New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.